Hemostemix to Present at Life Science Investor Forum

Core Insights - Hemostemix Inc. is a leading autologous stem cell therapy company, focusing on treatments for various cardiovascular diseases, and will present at the Life Science Investor Forum on September 18, 2025 [1][2][9] - The recent passage of Florida Senate Bill 1768 allows Hemostemix to legally offer its treatment, VesCell™ (ACP-01), to patients with no other options, expanding its market reach [2][3] - The company has achieved 498 successful treatments and has a strong clinical record supported by 11 peer-reviewed publications, positioning it as a leader in the global market for autologous stem cell therapy [3][8] Company Overview - Hemostemix was founded in 2003 and has developed the patented VesCell™ (ACP-01) therapy, which is designed to treat conditions such as peripheral arterial disease and chronic limb-threatening ischemia [10] - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of its treatments [10] - Hemostemix has received recognition as a World Economic Forum Technology Pioneer, highlighting its innovative approach in the healthcare sector [10] Clinical Evidence - The company has published 11 peer-reviewed articles that validate the safety and efficacy of its treatments, particularly for severe angina and various cardiomyopathies [8][10] - In a Phase II clinical trial for chronic limb-threatening ischemia, Hemostemix reported a 0% mortality rate and an 83% wound healing rate among patients followed for up to 4.5 years, significantly better than the typical 50% five-year mortality rate in this patient population [10]